Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development through 3D spatial biology

Alpenglow Biosciences collaboration with Mayo Clinic to integrate Alpenglow’s 3D spatial biology platform to accelerate drug development and advance clinical diagnostics. Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging, cloud-based, GPU accelerated bioinformatics pipelines, and AI-powered spatial analysis.

An abstract that will be presented at the American Association for Cancer Research Annual Meeting 2023, in collaboration with Dr. Janani Reisenauer, Dr. Eric Edell, and Dr. Christopher Hartley from Mayo Clinic, describes the application of Alpenglow’s 3D spatial biology platform to analyze human lung cancer samples from patients treated with immunotherapy, revealing novel 3D spatial insights that the team aims to correlate with treatment response.

Alpenglow’s platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and patient trial enrollment using their patented platform. Five of the top 10 pharma companies already work with Alpenglow to accelerate development timelines, save costs, gain